Immune-Boosting Effect of the COVID-19 Vaccine: Real-World Bidirectional Cohort Study

A Systematic Review of Trials Currently Investigating Therapeutic Modalities for Post-Acute COVID-19 Syndrome and Registered on World Health Organization International Clinical Trials Platform

(2023) Nader A. Fawzy et al.   CLINICAL MICROBIOLOGY AND INFECTION

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial

(2023) Rong Tang et al.   Lancet Respiratory Medicine

Study on the COVID-19 epidemic in mainland China between November 2022 and January 2023, with prediction of its tendency

(2023) Yao Bai et al.   Journal of Biosafety and Biosecurity

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

(2022) Sandile Cele et al.   NATURE

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

(2022) Raquel Viana et al.   NATURE

Homologous and Heterologous Covid-19 Booster Vaccinations

(2022) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization

(2022) Zhangkai J. Cheng et al.   ALLERGY

Association of Vaccination with the Persistence of Post-COVID Symptoms

(2022) Juan P. Wisnivesky et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England

(2022) Freja C M Kirsebom et al.   LANCET INFECTIOUS DISEASES

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

(2022) Gili Regev-Yochay et al.   NEW ENGLAND JOURNAL OF MEDICINE

A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial

(2022) Yu Cao et al.   Science China-Life Sciences

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

(2022) Pengfei Jin et al.   PLOS MEDICINE

The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study

(2022) Elke Wynberg et al.   VACCINE

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination

(2022) Fuzhen Wang et al.   Frontiers in Immunology

The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What

(2022) Ka-Wa Khong et al.   Vaccines

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

(2021) Houriiyah Tegally et al.   NATURE

Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries

(2021) Victoria Haldane et al.   NATURE MEDICINE

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

(2021) Nuno R. Faria et al.   SCIENCE

Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series

(2021) David T. Arnold et al.   ANNALS OF INTERNAL MEDICINE

Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity

(2021) Ramona Dolscheid‐Pommerich et al.   JOURNAL OF MEDICAL VIROLOGY

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

(2021) Shipo Wu et al.   LANCET INFECTIOUS DISEASES

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

(2021) Stephen J. Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human IgG and IgA responses to COVID-19 mRNA vaccines

(2021) Adam V. Wisnewski et al.   PLoS One

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

(2021) Lu Lu et al.   CLINICAL INFECTIOUS DISEASES

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum

(2021) Wanwisa Dejnirattisai et al.   LANCET

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

(2021) Ai-ris Y. Collier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India

(2021) Mahesh S. Dhar et al.   SCIENCE

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

(2021) Jingwen Ai et al.   Emerging Microbes & Infections

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

(2021) Li Zhang et al.   Emerging Microbes & Infections